Strategies and challenges for the next generation of antibody-drug conjugates. - sprookjes - yvandenbroek - TriplyDB

Strategies and challenges for the next generation of antibody-drug conjugates.

Strategies and challenges for the next generation of antibody-drug conjugates.

http://www.wikidata.org/entity/Q39182945

about

Bicyclic Peptides as Next-Generation Therapeutics.Emerging antibody-drug conjugates for treating lymphoid malignancies.Polymer therapeutics at a crossroads? Finding the path for improved translation in the twenty-first century.Chemically-defined camelid antibody bioconjugate for the magnetic resonance imaging of Alzheimer's disease.Insights from native mass spectrometry approaches for top- and middle- level characterization of site-specific antibody-drug conjugates.Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering.Drug discovery and therapeutic delivery for the treatment of B and T cell tumors.Opportunities for therapeutic antibodies directed at G-protein-coupled receptors.Current progress in innovative engineered antibodies.CEACAM1 as a multi-purpose target for cancer immunotherapy.Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer.Design and In Vitro Evaluation of a Cytotoxic Conjugate Based on the Anti-HER2 Affibody Fused to the Fc Fragment of IgG1.Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload.Cell-free synthesis of functional antibodies using a coupled in vitro transcription-translation system based on CHO cell lysates Harnessing a catalytic lysine residue for the one-step preparation of homogeneous antibody-drug conjugates Recent Developments in ADC Technology: Preclinical Studies Signal Future Clinical Trends.An update on anticancer drug development and delivery targeting carbonic anhydrase IX.Antibody-drug conjugate targeting protein tyrosine kinase 7, a receptor tyrosine kinase-like molecule involved in WNT and vascular endothelial growth factor signaling: effects on cancer stem cells, tumor microenvironment and whole-body homeostasis.Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?Intracellular Delivery of Native Proteins Facilitated by Cell-Penetrating Poly(disulfide)s.Visualizing endocytic recycling and trafficking in live neurons by subdiffractional tracking of internalized molecules.Delivering natural products and biotherapeutics to improve drug efficacy.The antibody-drug conjugate target landscape across a broad range of tumour types.Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer.A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors.Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads.A Chemoselective Rapid Azo-Coupling Reaction (CRACR) for Unclickable Bioconjugation.Mutation of Conserved Residues Increases in Vitro Activity of the Formylglycine-Generating Enzyme.Cell type-selective imaging and profiling of newly synthesized proteomes by using puromycin analogues.Development of Antibody-Directed Therapies: Quo Vadis?ASC amino acid transporter 2, defined by enzyme-mediated activation of radical sources, enhances malignancy of GD2-positive small-cell lung cancer.Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets.Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy.Antibody-drug conjugates: Design and development for therapy and imaging in and beyond cancer, LabEx MAbImprove industrial workshop, July 27-28, 2017, Tours, France.Fate of Antibody-Drug Conjugates in Cancer Cells.Therapeutic Targeting of Long Non-Coding RNAs in Cancer.Epitope characterization of anti-JAM-A antibodies using orthogonal mass spectrometry and surface plasmon resonance approaches.Influence of disulfide bond isoforms on drug conjugation sites in cysteine-linked IgG2 antibody-drug conjugates.Immunoprecipitation middle-up LC-MS for in vivo drug-to-antibody ratio determination for antibody-drug conjugates.Utilizing panels of patient derived xenografts to aid the development of antibody drug conjugates.

P2860

Q36394825-2789588B-BC74-4784-80D6-1CCB0CB8903E Q38632313-0B13B21A-7E62-4BEE-B343-54581F3FF5C0 Q38645927-59C97FD5-29F2-4AC5-99C0-0DAB45A4EE21 Q38665688-DF80324A-02BF-4CF8-9E82-B259E26C1D3B Q38838739-ECCC83B2-5443-4876-9DB9-F11DB9AD61A9 Q39279968-E736DCBF-2622-42EF-895B-FD3798DC69A7 Q39381251-D3919C73-F40F-4FB6-9A77-D0E366E5D83A Q39433833-041DD741-4276-429B-918A-87C4D659EFDE Q40077818-1C8C21F2-0C23-484F-A731-93B038DA8D4B Q41251368-2D32ECCE-22F4-4C7F-A139-62D84431C3D7 Q41514180-CAC838EE-917F-4C95-AC42-3BB3DE7CF1EF Q41573532-A9A9FD14-6E0B-4647-ABFF-D4882B533D8D Q41661216-882EEE5A-3DE4-4050-8DC5-26F06A9C0A7E Q41697029-3A21B0F8-8762-4BD6-A329-FFE512E73194 Q42646020-CC03B7EF-2BE2-4FA6-A2BB-6F82436BCC50 Q45728543-DAFECD3D-D163-4251-AD64-F61F25BFF295 Q47096060-14F27E9A-EDDA-420E-86D1-63449CC5D724 Q47112549-4D0AD57D-2238-4F71-BC7F-AB1FA4354775 Q47143718-2BB15B01-F040-4598-B54E-D946258C0436 Q47281816-D08C54D3-3966-44C3-8D51-05956394CD2C Q47299598-FA5E56E9-0B62-45C0-9ACE-6B8F5821D64D Q47419190-121C68F3-E246-4AC1-8C65-6AA2F958A360 Q47633328-ECD3168A-1CB6-41CC-8169-834C8A137984 Q47661007-5A042270-2F38-412B-ACAD-81E7958C5BEB Q47732625-A70FDDDE-EA42-4CC1-AD52-887465A9CFDF Q47804976-E6F3F717-B1BD-4AFB-8C46-E62F6233FFB4 Q47979016-4229AA90-C385-4BFA-BA5B-6D38A52CDBA9 Q48026798-425F1DC2-99F2-4479-A301-B2188682CE4D Q48135284-3FCC2A38-4E0C-4F4C-A747-CF8751019834 Q48228292-B43FC8C6-5DD2-40E5-BEA8-5DAAA6BABA66 Q48277237-2F4F6319-8261-4734-8457-91007A65019B Q49539698-EAABC25A-2E9A-4A1D-A08D-445852BB2308 Q49592680-D2C201B9-4AF4-4D9F-9F18-C88CB06BC608 Q49846411-68AA3F6B-8717-4FDD-A4A0-BC633C15AAF5 Q49883378-7B3A40A5-B478-4600-8ED8-60FFCD7A93E1 Q49961986-65ED8BEC-C528-4823-AAB1-1A755D627F72 Q49965683-B996EB98-0E49-48DB-B812-B110CFDC1EBD Q50046714-70C0BEEE-44E6-405E-AFB3-2233EBC5C7B2 Q50088579-8103F124-E4C1-4E92-8564-3DAD96BDF8F2 Q50195453-D56DED15-4438-4CC0-B95E-3F0C9F2C6324

P2860

Strategies and challenges for the next generation of antibody-drug conjugates.

http://www.wikidata.org/entity/Q39182945

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Strategies and challenges for the next generation of antibody-drug conjugates.

@en

Strategies and challenges for the next generation of antibody-drug conjugates.

@nl

type

label

Strategies and challenges for the next generation of antibody-drug conjugates.

@en

Strategies and challenges for the next generation of antibody-drug conjugates.

@nl

prefLabel

Strategies and challenges for the next generation of antibody-drug conjugates.

@en

Strategies and challenges for the next generation of antibody-drug conjugates.

@nl

P1433

Q39182945-75803918-3ACF-4CF8-9434-3E9E45057C4F

P1476

Q39182945-1207B00C-F2F3-44F9-9E50-A089859544E1

P2093

Q39182945-655204AB-2BE7-466A-BBCF-60C672445CA0

Q39182945-7222D95D-C505-4BC3-903D-E2D1B4F9ACFC

Q39182945-D06626C5-D3AE-4E31-9042-A3162C19B040

P2860

Q39182945-0146D365-AF96-4770-8BA5-4BDA74BA290F

Q39182945-01B445EC-DFB6-4E11-8729-7FE60D26FD99

Q39182945-026323AF-B012-46D2-BA97-4D27F3765C4B

Q39182945-0478C0FF-96BA-4216-94A7-2F6B9A857B68

Q39182945-04997E9F-0F80-429E-A178-3FACB24D472D

Q39182945-070EC31A-B28D-4E0D-86B6-615D49538372

Q39182945-0BFFCD08-C98E-4B80-B93F-033B2108AE54

Q39182945-0C62B934-74F0-4533-98EE-4BF6A6CCB31B

Q39182945-1017662F-94FC-40B8-BB1C-7F0A348265E1

Q39182945-102FAC68-F3B0-470A-81A6-1DF6C738385F

P2888

Q39182945-8FACCCD3-185A-4FE8-B185-6EDD1899BCB3

P304

Q39182945-45B2645B-D26A-4562-96B4-CC27CE846422

P31

Q39182945-5D8CB7AF-6131-4CAA-82DF-6B5A4D768599

P356

Q39182945-48ADA81F-F3EB-47F6-93C4-FD2F828A7E69

P433

Q39182945-0543E72C-8F61-40E4-9B22-A9557AD0D3A0

P478

Q39182945-DA5732F0-887F-42B3-91A6-F07CD2D2FC08

P50

Q39182945-5C5B07D1-E433-4FEF-AB7A-802F9C0D47E7

P577

Q39182945-34B903A7-EEDE-43ED-A3E0-A87385118697

P6179

Q39182945-DBBD0AAF-F3DC-4255-8F5A-414B3F81EA20

P698

Q39182945-23CE368A-C3F2-4D0B-B4EB-CE1712C65364

P921

Q39182945-82AD6B23-70F2-4AD5-BF81-0D51EB06C663

P356

P1433

Nature Reviews Drug Discovery

P1476

Strategies and challenges for the next generation of antibody-drug conjugates.

@en

P2093

Alain Beck

http://www.w3.org/2001/XMLSchema#string

Liliane Goetsch

http://www.w3.org/2001/XMLSchema#string

Nathalie Corvaïa

http://www.w3.org/2001/XMLSchema#string

P2860

An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations

Microtubule-binding agents: a dynamic field of cancer therapeutics.

Discovery of cytotoxic dolastatin 10 analogues with N-terminal modifications

Novel antibody-antibiotic conjugate eliminates intracellular S. aureus

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates

Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

Characterization of cysteine-linked conjugation profiles of immunoglobulin G1 and immunoglobulin G2 antibody-drug conjugates.

AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML

P2888

P304

315-337

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRD.2016.268

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-03-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1084129613

http://www.w3.org/2001/XMLSchema#string

P698

28303026

http://www.w3.org/2001/XMLSchema#string

P921